Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an update.
Vicore Pharma Holding AB has released its year-end report for January to December 2025, outlining its financial performance, development pipeline, and sustainability efforts. The report structure highlights CEO commentary, detailed financial information for both the group and parent company, and key performance measures, signaling a comprehensive disclosure aimed at investors and other stakeholders.
The most recent analyst rating on (SE:VICO) stock is a Hold with a SEK11.50 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a publicly listed biopharmaceutical company focused on developing pharmaceutical products, as indicated by its year-end financial reporting and pipeline disclosures. The company operates in the life sciences sector and reports on research pipeline progress, sustainability initiatives, and financial performance to its stakeholders.
Average Trading Volume: 616,920
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.92B
See more insights into VICO stock on TipRanks’ Stock Analysis page.